EE547 Impact of Inclusion of Finerenone in the Burden of Disease of Chronic Kidney Disease (CKD) in Type 2 Diabetes (T2D) in Central America

C. López-Cabra,Á.D. Rodríguez, W. Mayorga Mogollon, M.A. Chávez,A. Patiño, S.E. Herran, R. Marrugo

Value in Health（2023）

引用 0|浏览1

暂无评分

摘要

To estimate the impact on the burden of CKD-T2D from a social perspective in Central America with the standard of care (SoC) plus Finerenone, a nonsteroidal, selective antagonist of the mineralocorticoid receptor studied for the management of adults with CKD (eGFR ≥ 25mL/min with albuminuria) and T2D

查看译文

关键词

finerenone,chronic kidney disease,diabetes

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要